Mori Yuki, Motosugi Utaroh, Shimizu Tatsuya, Ichikawa Shintaro, Kromrey Marie-Luise, Onishi Hiroshi
Department of Radiology, University of Yamanashi, Yamanashi, Japan.
Department of Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, Greifswald, Germany.
J Magn Reson Imaging. 2020 Jan;51(1):62-69. doi: 10.1002/jmri.26760. Epub 2019 Apr 24.
Gadoxetic acid-enhanced hepatobiliary phase (HBP) is useful in liver MRI, but sometimes shows insufficient liver enhancement. There is no established method to predict insufficient liver enhancement before the contrast injection.
To reveal the utility of the Bayesian method for predicting patients with insufficient liver enhancement in the gadoxetic acid-enhanced HBP.
Retrospective.
In all, 576 patients with chronic liver disease.
FIELD STRENGTH/SEQUENCE: 3T/3D gradient-echo T -weighted imaging and MR elastography (MRE).
The patients were divided into two groups: insufficient and sufficient liver enhancement in HBP according to the liver-to-portal vein signal intensity ratio. Various parameters, including liver function tests and liver stiffness by MRE, were evaluated as predictors of insufficient liver enhancement.
We used Chi-square/Student's t-test/logistic regression analysis to determine independent associates, and Bayes' theorem to estimate the probability of insufficient (or sufficient) liver enhancement. The feasibility of Bayesian prediction of insufficient liver enhancement was tested by leave-one-out cross-validation to calculate sensitivity and specificity for single variables and combinations of some variables in all patients and in a subpopulation showing a confidence level of >80%.
Independent associates of insufficient liver enhancement in HBP included: serum albumin (odds ratio [OR] = 4.82, P < 0.001), total bilirubin (OR = 0.30, P < 0.00), platelet count (OR = 1.54, P < 0.00), and liver stiffness by MRE (OR = 0.59, P < 0.00). The accuracy of Bayesian prediction of insufficient liver enhancement was 80.9% (466/576) for the single parameter of albumin and 79.0% (455/576) for total bilirubin, and was increased to 85.2% (487/576) for a combination of albumin, total bilirubin, and liver stiffness. In patients who showed a confidence level of >80%, the accuracy was 89.0% (439/493) for the above combination.
Bayesian prediction was useful to predict patients with insufficient enhancement by combining serum liver function tests and liver stiffness by MRE.
3 Technical Efficacy Stage: 5 J. Magn. Reson. Imaging 2020;51:62-69.
钆塞酸增强肝胆期(HBP)在肝脏磁共振成像中很有用,但有时肝脏增强不足。在注射造影剂之前,尚无预测肝脏增强不足的既定方法。
揭示贝叶斯方法在预测钆塞酸增强HBP中肝脏增强不足患者方面的效用。
回顾性研究。
总共576例慢性肝病患者。
场强/序列:3T/3D梯度回波T加权成像和磁共振弹性成像(MRE)。
根据肝脏与门静脉信号强度比,将患者分为两组:HBP中肝脏增强不足和增强充分。评估了各种参数,包括肝功能检查和MRE测量的肝脏硬度,作为肝脏增强不足的预测指标。
我们使用卡方检验/学生t检验/逻辑回归分析来确定独立关联因素,并使用贝叶斯定理来估计肝脏增强不足(或充分)的概率。通过留一法交叉验证来测试贝叶斯预测肝脏增强不足的可行性,以计算所有患者以及置信水平>80%的亚组中单个变量和某些变量组合的敏感性和特异性。
HBP中肝脏增强不足的独立关联因素包括:血清白蛋白(优势比[OR]=4.82,P<0.001)、总胆红素(OR=0.30,P<0.00)、血小板计数(OR=1.54,P<0.00)和MRE测量的肝脏硬度(OR=0.59,P<0.00)。对于白蛋白单一参数,贝叶斯预测肝脏增强不足的准确率为80.9%(466/576),对于总胆红素为79.0%(455/576),而白蛋白、总胆红素和肝脏硬度组合的准确率提高到85.2%(487/576)。在置信水平>80%的患者中,上述组合的准确率为89.0%(439/493)。
通过结合血清肝功能检查和MRE测量的肝脏硬度,贝叶斯预测对于预测增强不足的患者很有用。
3 技术效能阶段:5 《磁共振成像杂志》2020年;51:62 - 69。